Danish Drugmaker Novo Nordisk has agreed to pay $25 million to settle a lawsuit over improperly marketing its anti-clotting medicine, NovoSeven. Allegedly, Novo Nordisk marketed NovoSeven for off-label uses not approved by the FDA. In addition, it will pay $1.725 million to resolve claims its sales representatives paid Rite Aid pharmacists to recommend Novolin and Novolog to treat diabetes.

Novo Nordisk also agreed to a five-year corporate integrity agreement with the U.S. Health and Human Services department, which will require the drugmaker to revise its internal compliance guidelines.

Read the entire article, “UPDATE 2-Novo Nordisk settles U.S. probe for $25 million”